SLC16A1 and cholangiocarcinoma: To our knowledge, this is the first study to describe the role of SLC16A1 in drug resistance in CCA, and targeting SLC16A1 with combination therapy or developing specific inhibitors may become an effective strategy to improve the treatment of CCA.